Zacks Small Cap Research is a Benzinga Contributor

Articles written by Zacks Small Cap Research

Biotech

News

Penny Stocks

Events

Markets

Trading Ideas

General

MIRA

By Brad Sorensen, CFA

READ THE FULL MIRA RESEARCH REPORT

MIRA Announces Positive Test Results

ADAP

By Michael Kim

READ THE FULL ADAP RESEARCH REPORT

ADAP: Initiating Coverage of Adaptimmune, a Leading T-Cell Therapy Company

Tech

Nuveen California Dividend Advantage Municipal Fund 2

By M. Marin

EV + hybrids 12.7% of Ford&#39;s ‘24 vehicle sales to-date vs 8.3% in same period of ‘23… 

NVX: Positive Takeaways Recent EV Sales Trends

BBLG

By Brad Sorensen, CFA

READ THE FULL BBLG RESEARCH REPORT

BBLG Continues Progress as Testing Proceeds

Global

CART

GTOFF

WBUY

By Brian Lantier, CFA

We are initiating coverage of Webuy Global (NASDAQ: WBUY) with a $0.85 target valuation.

Initiating Coverage of a Southeast Asian Community-Based Buying Group

Small Cap

Shareholder letter regarding next month&#39;s annual meeting 

TRC: Annual Meeting Next Month; Stockholder Issues Letter to Others

Health Care

ADMT

ADM Tronics (OTC: ADMT) is a diversified technology company, specializing in the development and manufacturing of innovative products across three primary areas including Proprietary Electronic Medical Devices, Engineering, Regulatory, and Manufacturing Services, and Eco-Friendly, Water-Based Formulations.

Advancements in Medical Device Innovation

HOFV

LUXH

PRKS

LuxUrban Hotels Improvements in Working Capital and Free Cash Flow in 2024 Supports Price Target of $5.00

SNGX

By David Bautz, PhD

Business Update

Reaches Agreement with European Medicines Agency on Second Confirmatory Trial for HyBryte™

SNGX: Agreement with EMA on Second Confirmatory Trial for HyBryte™

CRVO

By David Bautz, PhD

Business Update

Biomarker Data Presented at AD/PD 2024

CRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24

Earnings

SDOT

Sadot Group Potential Profitable Growth Going Forward Supports Price Target of $3.50.

IRME

IR-Med&#39;s Potential for Profitable Growth in Coming Years Supports Price Target of $3.00

HTCR

HTCR: HeartCore Announces Sale of $9.0 Million in Go IPO Client Warrants

BioStem Technologies (OTC: BSEM) Report by Zacks Investment Research

Analyst Ratings

BSEM

The below report was authored by Brad Sorensen, CFA, Zacks Small Cap Research. You can find the original report here.

 

BioStem Technologies (OTCMKTS: BSEM) Coverage Initiated at Zacks Investment Research

PNDHF


  By M. Marin

OTCQB:PNDHF | TSX.V:POND

READ THE FULL PNDHF RESEARCH REPORT

PNDHF: Insider Participation in Private Placement Underscores Management&#39;s Confidence in Company Prospects

FRXIF


  By Brad Sorensen, CFA

OTC:FRXIF

READ THE FULL FRXIF RESEARCH REPORT

FRXIF: A Stock On the Cusp of Catching On Fire

CLMEF

CLMEF: An Energy Company with an Enticing Yield

VICTORY SQUARE TECH ORD by Victory Square Technologies Inc

VSQTF


  By Lisa Thompson

OTC:VSQTF

READ THE FULL VSQTF RESEARCH REPORT

VSQTF: Q2 Report at Victory Square Shows Rapid Growth at IV Hydreight and XR Immersive

GBLI


  By Thomas Kerr, CFA

NYSE:GBLI

READ THE FULL GBLI RESEARCH REPORT

GBLI: INITIATION: Smallcap specialty property &amp; casualty insurer entering a new and focused growth phase. The company operates in specialty areas primarily in excess and surplus lines.

Application error: a client-side exception has occurred (see the browser console for more information).